Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia
Phase 2
Completed
- Conditions
- Type II Hyperlipidaemia
- Interventions
- Drug: PlaceboDrug: JTT-705 300mgDrug: JTT-705 600mgDrug: JTT-705 900mg
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2008-05-29
- Lead Sponsor
- Japan Tobacco Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT00686010
- Locations
- 🇳🇱
Amsterdam, Utrecht, Rotterdam, Nijmegen, Arnhem, Groningen, Dordrecht, Hoorn, Groningen, Amsterdam, Netherlands
© Copyright 2025. All Rights Reserved by MedPath